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Introduction
1INTRODUCTION
Bacterial vaginosis is due to imbalance in the normal bacterial
flora  of  vagina.  Bacterial   vaginosis   is   a   polymicrobial   syndrome
involving the replacement  of  the  normal  vaginal  lactobacillus  by
variety  of anaerobic  bacteriae  and  mycoplasmas.
Bacterial   vaginosis   is   the   commonest    cause   of   vaginal
discharge  ( 48% ) in  women  with  significnt  morbidity.1 If  untreated ,
patients   are   more   prone   for   ascending   endometrial   infections,
preterm   delivery   and   increased   risk   of   acquisition    of   Herpes
genitalis, Gonorrhoea  and   HIV  infections. Most  of  the  cases   are
asymptomatic  and  recurrences  are  common   even  in  treated  cases.
Recurrence  of  the  disease , unknown  incubation  period , adverse
outcomes  on  pregnancy  and  complications  like  pelvic inflammatory
disease  necessitated  the need  to  find  an  alternative  drug ,  in  this
emerging  antibiotic  resistance  period.
In   this   background   we   planned   to   conduct   this   study   to
compare  the  efficacy  of    Metronidazole , the  commonly  used  drug
and  Lactobacillus ,  a  Probiotic  alternative  drug.
Review of
Literature
2REVIEW OF LITERATURE
DEFINITION
           Bacterial   vaginosis   is   the   most    common  form  of   vaginal
infection  in  women  of  the  reproductive  age  group  which  represents
a  disturbance  of   vaginal   microbial   ecosystem  rather   than  a   true
tissue   or   epithelial   infection.  It   is   a   polymicrobial   syndrome
involving  replacement  of  the  normal  vaginal  lactobacilli  by  a
variety  of  anaerobic  bacteria  and  mycoplasmas.2
SYNONYMS
           Non specific vaginitis, Hemophilus vaginitis, Corynebacterium
vaginitis, Gardnerella vaginitis, nonspecific vaginosis, anaerobic
vaginosis.
EPIDEMIOLOGY
? It accounts for 48% of patients with abnormal vaginal discharge.
? The   prevalence   of   bacterial   vaginosis   among   adolescents
varies  from  13%-31.9%3
3? Among   post  pubertal   females  ,  the   prevalence   of   BV    was
lower  with  those  who  had  no  sexual  experience  than  those
with  sexual  experience.4
? BV is  more  prevalent  in  patients  with  tubal  infertility
(31.5%) as  compared  with  non  tubal  infertility. (19.7%) 5
? Among  lesbians   the  prevalence  is  29%. 6
? High  prevalence  rates  are  seen  in  HIV  positive  commercial
sex  workers.7
VAGINAL ECOFLORA
      The  vagina  is  a  dynamic  ecosystem  that  is  sterile  at  birth.
Under   the influence  of  maternal  oestrogen  the  glycogen   content  of
vaginal  epithelial   cells   get   elevated   and   the   infant   vagina   is
colonised  by lactobacilli.
          As  the  level  of  oestrogen  diminishes,  the  glycogen  content
and   the   lactobacilli   diminishes,   which   contribute   to   interspersion
with  coagulase  negative  staphylococci, streptococci   and  E.coli
colonisation.8
4In   the  adult  female  once  again  due  to  increased  glycogen
under  the  influence  of   oestrogen ,   the   lactobacilli    concentration
rises to  about  105 -108 cfu/ml  of  vaginal  secretion. Other   organisms
are present at concentrations as below
Gardnerella vaginalis 107
Mycoplasma hominis 10 5.2
Anaerobic gram negative rods 106
Privately biviadisiens10 5.5
LACTOBACILLUS
             Various  subspecies   of   lactobacillus  are  present   in  vagina
like  Lactobacillus  jensensinii, L.crispatus, L.gasseri, L.fermentum,
L.oris, L.reuteri  and  L.vaginalis.9
1. They  produce  Hydrogen  peroxide  which has inhibitory
effect on bacterial  growth , particularly  catalase  negative
bacteria.
2.  Hydrogen  peroxide   also   interacts   with   halide   ions   in
the   presence   of   cervical   peroxidase  and   forms
H2O 2–halide-peroxidase  antibacterial  system  which
inhibit  bacteria  as  well  as  viruses  including  HIV.
53.  Lactobacillus also produces bacterial interference by
colonisation.
VAGINAL pH
            Vaginal pH in premenarchal female is near neutral
(around 7).
             At  the  time  of  puberty,   the  vaginal  epithelium  increases  to
25  cell  thickness,  glycogen  level  increases, there is  predominance  of
Lactobacillus  and  the production  of  lactic  acid  decreases  vaginal
pH  to  less  than  4.5 .This  pH  is maintained  until menopause.
PATHOGENESIS OF BACTERIAL VAGINOSIS
In   BV,   this   symbiotic   relationship   is   broken   up   and
overgrowth  of   pathogenic  anaerobic  bacteria  produces  amines  by
decarboxylation  of  fatty  acids  and  amino acids  which  elevates  the
vaginal  pH.
            The  effects  of  altered  pattern  of  organic  acids  is  uncertain.
Succinic   acid   produced   by   vaginal   anaerobes   inhibit   the
chemotactic  response  of  WBC.10
6          The  vaginal  fluid  of  women  with  BV  has  increased  levels  of
endotoxin, sialidase,and  mucinase.An  increased  host  response is
documented  by  increased  levels  of  IL 1 ? and  prostaglandins  in  the
cervical  mucus. 11
BIOCHEMICAL CHANGES
           There   is  increased  microbial  surface  virulence  factors
including  lipopolysaccharidases,  sialidases , mucinases.   In  addition
some  strains  of  Gardnerella  vaginalis  cause  cleavage  of  secretory
IgA.12
            Anaerobic bacteria produce enzymes, aminopeptidases that
degrade protein.  Decarboxylase  convert  amino  acids  and  other
compounds   to   amines   such   as   putrescine,  cadaverine   and
trimethylamine  at  alkaline  pH. These  amines  contribute  to  increased
vaginal    pH    and   produce   odoriferous   discharge.Mobiluncus   is
known  to  produce  trimethylamines.13
             The  vaginal  fluid  of  women   with  BV  has  increased  levels
of  endotoxin,sialidase  and  mucinase .
7                An  increased  host  response  is documented  by  increased
levels  of   IL1?  and   prostaglandins   in   the   cervical   mucus.
The  redox  potential   (eh)  of   vaginal   epithelial   surface   is
lower  in  women  with  BV.
RISK FACTORS
     1. History of bacterial STDs
      2. Increased number of lifetime sexual partners.14
      3. Lower age of first intercourse 15
      4. Lesbians 16
       5. Smoking
        6. High risk sexual behaviour
7. Intrauterine contraceptive devices 17, vaginal douching,
peccary use.
        8.  Gynaecological cancers 18
CLINICAL FEATURES
Symptoms:
            Malodorous vaginal discharge, more after sexual intercourse and
during menstruation.
8            Pruritus (very rarely)
            Pain during coitus
            Lower abdominal pain
            Mental stress due to the symptoms
Signs:
    Gross vaginitis and vulvitis are not characteristic of this
condition.
              1. Excessive ,homogenous  uniformly  adherent  vaginal
discharge,  in contrast  to the  floccular  vaginal   discharge
of  normal  individuals.
              2.  Elevated vaginal pH >4.5. pH  determination  is  assessed
by  narrow  range  pH  paper  applied  to  the  withdrawn
speculum  or directly  over  the  vagina.If  it  is  more than
4.5  then  it  is  abnormal.19
              Also  vaginal pH can be assessed   by self test pH glove. In this,
One  finger  of   a  medical   examination  glove  has  an  attached  pH
indicator  which  the patient  can  introduce  into  her  vagina  and  then
read  the  measured  result.20
93.  Sniff / Whiff test:
The  odour  of   vaginal   secretions  is   tested  by  smelling  the
withdrawn  speculum. Rotten  or  dead  fishy  odour  is  smelt  due  to
the  presence  of  amines  like  putrescine, cadaverine  and trimethy
lamine.
This  can  also  be  tested  by  adding  a  few  drops  of  10% KOH
to   a   few   drops   of   vaginal   secretion.  The  test  will    give  the
characteristic odour.
The  KOH  test  was  reported to be   the  most  powerful  single
predictor   for   the   diagnosis   of   BV .  This   test   may   be   the   least
sensitive  of  the  clinical  tests  for  diagnosis  of  BV.
            Electronic  sensor  assay ( electronic  nose )  The  idea  of  using
sensor  arrays  coupled  with  interpretation  of  the  resulting  signals  is
based  on the  assumption  that  the signal  pattern  detected  might  be
an  electronic  counterpart  to  the  human  sensation  of  smell  and  has
attracted  some  attention.
            4. Saline  wet  mount  and  gram staining  of  vaginal  secretion
should  be  done  to  look  for  clue  cells.
10
Clue  cells  are  squamous  epithelial  cells  with  large  number
of  BV  organisms  densely  attached  in  clusters  to  their   surface. The
cell  borders  are  not  clearly  discernible, with  fuzzy  cytoplasm , like
staining  with  black  pencil. 21
The  presence  of  >  20  %  of  clue  cells  is  diagnostic.  Clue  cells
represent the best single diagnostic criteria of BV.
    5. Absent or few lactobacilli in Gram staining.
AMSEL’S CRITERIA:
1.  Excessive, homogenous , uniformly adherent vaginal
discharge
2.  Elevated vaginal  pH  >  4.5
3. Positive  amine  test ( Whiff  test )
4.  Clue  cells  constituting  20%  or  more  of  total  vaginal
epithelial  cells.
             The above four   diagnostic features are the features of Amsel’s
criteria. The  patients  should  fulfil    at least  3  out  of  4  criteria  for
bacterial  vaginosis. 22
11
NUGENT’S SCORING SYSTEM
              Vaginal  Gram  stain  had  comparable  sensitivity  but  a  much
greater   specificity   and   predictive   value   than   vaginal   culture   for
G.vaginalis.Culture   does   not   constitute   test   of   cure  ,  since   many
women  without  clinical  signs  of  BV  have  positive  culture  for  this
organism  following  treatment. 23
               This system is based on the bacterial morphology in   Gram
staining.
Bacterial morphology type    Score:  none      0 1+       2+     3+    4+
Lactobacilli                                                  >30   6-30   1-5    <1    0
(large, elongated, gram
Positive bacteria)
Gardnerella vaginalis  0 <1    1-5    6-30     >30
(Small, Gram variable
Coccobacilli)
Mobiluncus 0 <1     1-5     6-30    >30
(Curved, gram negative
Bacilli)
SCORE                             0-3       Normal
4-6 Intermediate ( test   to be  repeated
later)
7-10 Bacterial  vaginosis
12
SCHMIDTS   SCORING SYSTEM
This  system  of  wet  smear  examination  of  vaginal  secretion
resembles  Nugent’s  scoring  system. The  ranking  of  lactobacilli and
cocci  is similar but the  demarcation  of  the  intervals  differ. 24
This system does not recognise mobiluncus.
This  method  has  been  validated  for  the  diagnosis  of  BV  in
primary  care  population.
HAYS/ ISON SYSTEM
This  is  another  scoring  system  based  on  the  observation  of
gram  stain  to  estimate  the  ratios  of  the  observed  morph type  rather
than  the  exact  number  of  bacteria.
Originally the observations are divided into three   categories -
normal, intermediate or BV. Later , in  order  to  obtain  a  more  precise
classification , two  additional  categories  were  added  as  compared  to
Nugent’s  scoring. The  new  groups  are   those that contain no  bacteria
at  all  ( Group  0 ) and  those that  contain   large  amounts  of  gram
positive  cocci  such  as  streptococcus  or  staphylococcus
morphotypes.25
13
DIAGNOSIS
        1. History, Clinical examination
         2.  Satisfying Amsel’s criteria, Nugent’s scoring
         3.  Gas liquid chromatography   for succinate and lactate ratio
Many  anaerobic  Gram  negative  rods  produce  succinate,  as  a
metabolic  product  and  lactobacilli  produce  lactate,  as  a  metabolic
product.  The   ratio   of  succinate   to   lactate   has   been   found   to   be
increased  in  vaginal  fluid  of  patients  with  BV. This is done by gas
liquid chromatographic analysis. 26
        4. Amine estimation;
Diamines   and   polyamines   in   the    vaginal   fluid   show  86%
sensitivity  and  92%  specificity  by  Femexam  method. They can also
be estimated by colorimetric detection of diamines. 27
        5.   Serodiagnosis   to  determine  the  presence  of   antibodies  to
the  microbes.
        6. Nucleic acid probe
7. DNA probe 28
         8. Culture
14
Gardnerella  Vaginalis:   Semi selective  human  blood  in  Tween
80 bilayered  agar  + 5% Carbon di oxide  will  give  tiny  colonies with
a  zone  of  haemolysis  in  a  period  of  3-5  days. G.vaginalis  can  be
recovered  from  all  women  with  BV  but  also  from  upto  58%  of
those  without  BV.
Mobiluncus:   Human  blood  Colombia  agar  or   semi selective
foetal   calf   serum   and   rabbit’s   blood   bilayered   agar   with   5%
Carbon di oxide yields  tiny  translucent  colonies   in  3-5  days.
Mycoplasma hominis:  Hominis agar or H-H broth with arginine
will give a fried egg colony.
9. Detection of metabolic products:
            Proline  amino  peptidase  test – Bacteria  associated  with  BV
produce  proline aminopeptidase , whereas  lactobacilli  do  not  produce
this  enzyme.
             After   inoculation  of  vaginal  fluid  with  enzyme  substrate  in
a   micro  titre   plate   for   4  hours   at   35.5º  C,  rapid   garnet   green   is
added  to  produce  a  colour  reaction. Red  or  pink  colour  indicates  a
positive   test   whereas   an   orange   or   yellow   colour   indicates   a
15
negative   test.  It  was  reported  to  have   81%  sensitivity   and   96%
specificity  in comparison  to  clinical  criteria  for  diagnosis  of  BV. 29
10. BV blue test:
It is a test for detection of sialidases activity. A  vaginal  swab  is
to   be   placed   in   the    BV  Blue   vial   containing   the   chromogenic
substance   of   bacterial   sialidase   and   a   laboratory   timer   is   to   be
started. Two drops  of  BV Blue  developer  solution  is  to  be  added at
10   minutes.  Blue   or   green   colour    was   recorded   as   a   positive
result, whereas   yellow  colour  represents  negative  result. The test is
performed at room temperature.
11. Pulse field gel electrophoresis rib typing
12. 16S rand restriction fragment length polymorphism
13.  Multiplex polymerase chain reaction
14. Triplet arbitrary primed PCR
16
DIFFERENTIAL DIAGNOSIS
PHYSIOLOGICAL
1. At  the  time  of  menarche
2. At the time of menopause
3.  After   sexual intercourse
4. At the time of ovulation
5. Before and after menstruation
6. Pregnancy
PATHOLOGICAL
Vaginal discharge is considered abnormal if
1. Hypervaginal  secretion  not  associated  with  menstruation
2.   Offensive or malodorous  discharge
3. Yellowish discharge
INFECTIVE
Vaginitis   -     Bacterial vaginosis
Vaginal candidiasis
17
Vaginal trichomoniasis
Cervicitis   -    Neisseria gonorrohoeae
Chlamydia   trachomatis
NON INFECTIVE
    Foreign bodies - IUCD
Tampons and other materials
Chemical   irritants - Antiseptics
Deo spray
Bath additives
Detergent, spermicidal agents
Douches
Perfumed   soaps
Gynaecological conditions – Endo  cervical polyps
Fistulae
Post operative
     Radiation effects
Tumours
Medication and nutrition 30
18
COMPLICATIONS
Gynaecological  complications:
1. Plasma  cell  endometritis
2. Silent   endometritis   -   Spontaneous   PID  that   occurs   without
instrumentation   may  also  be  related  to  BV. A small  amount
of  intermenstrual  bleeding  or  increased  bleeding  with  menses
is a frequent occurrence in patients with endometritis and
salpingitis.31
3. Vaginal  cuff  cellulitis
      4.  BV  and  HIV   -  There  is  a  twofold  increase in the  prevalence
of   HIV   in   women   with   BV.  Women   with   BV   are  more
likely  to  seroconvert  to  HIV  than  those  without  BV.
A  low  vaginal   pH  inhibit   CD4 lymphocytes  activation  and
reduces   the  target  for  HIV  in  the  vagina. In  BV,  elevated   vaginal
pH   makes   the   vagina   more   conducive   to   HIV   survival   and
adhesion.The   level   of   acidity   of   vagina   may   affect   CD 4
lymphocytes  activation. The  more  alkaline the pH , more  CD 4 cells
are activated  and  is a  more  suitable  target  for  HIV.
BV also increases IL -10, which increases   the susceptibility
to HIV.
19
Main  degrading  enzymes  in   BV  will  make  it  easier  for  HIV
to  infect,  by  breaking  down  the  cervico  vaginal  mucus. 32
BV and other STIs
BV  is  present   most  frequently  as  a  co infection   with  other
STI s   like   Gonorrohoea.The  leading  hypothesis  to  explain   this  is
that  the  absence  of  protective  Lactobacilli  in BV  facilitates  the
acquisition  of  other  STIs. 33
An   inhibitory  effect  of  the  bacterial  amines  putrescine  and
cadaverine   on   the   cell    division   and    germ   tube   formation  of
candidia  albicans  has  recently  been  reported. 34
Obstetric complications
1. Intra  amniotic  fluid  infection  -  BV  associated  organisms
ascend  to  cause  infection  of  the  decidua , placenta  or
amniotic  fluid . Those  patients , have  elevated  levels  of
endotoxin   on    activation   of   the   prostaglandin   system  and
could  provoke  preterm  labour. The concentration of PGE 2 and
PG  F2 are  significantly  higher.  Even   in   the   absence   of   upper
genital  tract  infection, BV  associated  pathophysiology  might
lead  to  preterm  labour. 35
20
2. Chorioamnionitis
3. Premature  rupture  of  membrane
4. Preterm  delivery
5. Low  birth  weight
6. Post partum  endometritis
7. Post abortion endometritis -  Invasion  of  anaerobes  like
Gadnerella  vaginalis and  Mycoplasma  hominis  increases  the
risk  of  postpartum  endometritis and vaginitis   if  delivered
vaginally  or  by  LSCS.
 TREATMENT
The  cure  or  improvement  was  usually  defined  as  resolution
of  two  or  more  of  Amsels  criteria  for  diagnosis. 36
TREATMENT GUIDELINES
WHO (2003)
Recommended regimen
? T. Metronidazole  400 mg  or  500 mg  orally, twice  daily  X  7
days.
21
Alternative regimen
? T .Metronidazole  2  gm  orally  as  a single  dose  or
? Clindamycin   2  %   vaginal   cream,  5   gm   intra  vaginally    at
bedtime for  7  days   or
? Metronidazole  0.75%  gel, 5 gm  intravaginally , twice  daily  for  5
days  or
? T.Clindamycin 300 mg orally twice daily for 7 days.
CDC guidelines (2006):
Recommended   regimen:
? T.Metronidazole  500  mg  orally  twice  a  day  for  7  days  or
? Metronidazole   gel   0.75  %   one   full   applicator   (5  gm  )
intravaginally  once  a  day  for  5  days  or
? Clindamycin  cream  2 % one  full  applicator ( 5 gm ) intravaginally
at  bedtime  for  7 days.
Alternative regimen:
? T. Clindamycin  300  mg orally  twice  a  day  for  7  days  or
? Clindamycin  ovules  100  mg  intravaginally  once  at  bedtime for
3 days
22
NACO   guidelines (2007):
Recommended guidelines   for vaginitis (TV, BV & VVC):
           T.Secnidazole 2 gm orally single dose
                           Or
           T. Tinidazole 2 gm orally twice daily for 5 days.
           T.Metaclopramide  to  be  taken  30  minutes  before  T.
Secnidazole  to  prevent  gastric  intolerance.
Along  with   T.  Fluconazole   150   mg  orally   single   dose   (or)
Local  Clotrimazole  500mg  vaginal  pessary  once. 39
Gardnerella   vaginalis   is   more  susceptible  to  the    hydroxyl
metabolite  of  metronidazole.Mycoplasma  curtissii  is  not  susceptible
to  metronidazole. The  long  term  recurrence  rate  following
Clindamycin   and   Metronidazole   approach   80%  in   the   year   after
treatment. 38
Alternative  treatments  for  BV  includes restoration  of  normal
vaginal  ecology ;
1. Chlorhexidine  pessaries  150 mg x 7 days
2. Povidone  iodine  pessary  bid  x 14 days
23
3. The   use   of   vaginal   acidifiers   in   the   form   of   gels,
suppositories,    and  acid  soaked  tampons  has  varied  widely
from  18-80%
        They suppress but do not kill vaginal anaerobes.
Lactic acid suppository:
 Lactate pH 3.5, 5 gm gel daily x 7 days
 Lactate pH 3.8, 5 gm gel intermittent use x 6 weeks
Acetate gel:
           5% Acetic acid tampon bd x 7 days
Yogurt;
         PH < 4.5 douche 10-15 ml bd x 14 days
         Lactobacillus suppository bid x 6 days
Hydrogen  peroxide  producing  lactobacillus  acidophilus  in
combination  with  0.03  mg  of  estriol.
Unresolved issues in the patient management
1.  How common is late recurrence?
Up to   70  % women  develop   recurrent   BV within   3   months
after  therapy.40 Other  studies  show  long  term   recurrence  rates  of
approximately  50%.41
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2.   Why do recurrences happen?
a. Reinfection by a male partner colonised with BV associated
micro organisms.
b.  Recurrence due to the persistence of BV associated
organisms.
c.  Failure  to  establish  the  normal  and  perhaps  protective
lactobacillus   rich  flora  following  therapy.
d.  Persistence  of   another  yet   unidentified  host   factor   in
the  patient.
e. Microbiological  studies  established  that  half  of  women
lack  vaginal lactobacilli  that  produce H2 O 2 following
therapy  with  clindamycin  or  Metronidazole. 42
3. Should women with signs of BV be treated if asymptomatic?
Women  with  BV  should  be  informed  of  their  diagnosis  and
treatment  should  be  offered  if  requested.
4.    Does   BV   contribute    to   PID   among   women   undergoing
IUCD  insertion ?
IUCD users are at increased risk of BV. It  also  increases  the
risk  of  endometritis  and  salpingitis  following  IUCD  insertion.
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5. Should  HIV  infected  women with  asymptomatic  BV  receive
treatment  ?
          HIV  infection  may  be  particularly  common  in  BV  associated
PID.It  may  be  prudent  to  recommend  treatment  of  asymptomatic
BV  in  HIV  infected  women.
6.  Should male partners be treated?
          No   study   has   convincingly   shown   that  treatment   of   male
partners  decrease  the risk  of  recurrence. 43
PREVENTION
       1.  Abstinence
       2.  Promotion of condom use
        3. Recolonization of vagina with H2O2 lactobacilli
        4.  Genital hygiene practice in the male partner. 44
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METRONIDAZOLE
History
           Isolation  of  the  antibiotic  azomycin ( 2-nitro-imidazole) from
a  streptomycete  by  Maeda  in  1953. 1- ?-hydroxyethyl-2 methyl-5-
itroimidazoles   has   especially   high   activity   in   vivo   and   in   vitro
against  the  anaerobic  protozoa  T.vaginalis  and  E.histolytica . 53
PHARMACOLOGY
          Metronidazole is an amoebicidal, trichomonicidal and
bactericidal drug.A chemically reactive  reduced form of  metronidazole
is  thought  to  be  responsible  for  the  drug’s  activity. The  reduced
substrate  affects  anoxic  or  hypoxic  cells  causing  loss  of  the  helical
structure  of  DNA  strand  and  impairment  of  cellular function.
SPECTRUM OF ACTIVITY
1. Anaerobic  gram  negative  bacilli  including  most  bacterioides
species, fusobacterium  and  veillonella.
2. Anaerobic  gram  positive  cocci  including  clostridium,
eubacterium,peptococcus  and  peptostreptobacillus.
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3. Helicobacter  pylori, Gadnerella  vaginalis  and  the  protozoa
Endamoeba  histolytica, Trichomonas  vaginalis  and  Giardia
lamblia.
4. Not  against  fungi, viruses  and  most  other  aerobic  or
facultative  anaerobic  bacteriae  like  Actinomyces, Lactobacilli
and  Propionio bacterium  acnes.54
MECHANISM OF ACTION
1.  It  is  a  prodrug. It  requires  reductive  activation  of  the
nitro  group   by   susceptible   organisms.  The   anaerobic
organisms  contain  electron  transport   components  such
as ferredoxins, small Fe –s proteins that have a  sufficiently
negative  redox  potential   to  donate  electrons   generated
by energy  metabolism.The  single  electron  transfer  forms
a   highly  reactive  nitro  radical  anion  that  kills  the
susceptible  organisms  by  targeting  DNA and  other  vital
bio  molecules.
The   anaerobic   organisms    derive   energy   from    the
oxidative  fermentation  of   keto acids  such  as  pyruvate.
Pyruvate   decarboxylation  catalysed  by  pyruvate :
ferredoxin   oxido reductase (PFOR) produces  electrons
that  reduce  ferredoxins which  in turn catalytically
28
donates  its electrons  to  biological electron acceptors  or
to  metronidazole.55
2.  Suppression of cell mediated immunity.
3.  Sensitization  of  hypoxic   cells  to  radiation,
carcinogenicity  and  mutagenicity  in  experimental
animals.
CLINICAL RESISTANCE
1.  When  there is  impaired  oxygen  scavenging  capabilities,
there  will  be  increased  local  concentrations  of  oxygen.
This causes decreased activation   of Metronidazole.56
2.   Lower   levels   of   PFOR   and   ferredoxin    owing   to
reduced  transcription  of the  ferredoxin  gene.57
3.   Increased   expression of superoxide dismutase and
peroxiredoxin also cause Metronidazole resistance.
PHARMACOKINETICS
Following oral administration, Metronidazole is well absorbed
from the gastrointestinal tract.
         Peak  serum  levels  following  an  oral  dose  occurs  in  1  to  2
hours.  Mean   effective   concentrations   in   plasma   of   8-13   micro
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gm/ml  is  achieved  within   0.25   to   4   hours   after   a   single   dose
of  500 mg.
Repeated  doses   every   6   to   8   hours   result   in   some
accumulation  of the  drug. The plasma half life is 6 to 8 hours.
         It   reaches  cell,   tissues  and  fluids  with  CSF  concentrations
reaching  approximately  43% of  serum  concentration.
         The drug crosses the placenta and is secreted in breast milk.
Metronidazole is metabolized in the liver. It  is  excreted  primarily  in
the  urine   as   metabolites   with   20%   of   the   dose   excreted    as
unchanged drug.
         The  half  life  of  Metronidazole  in  adults  ranges  between  6
and 12 hours. Accumulation may occur in patients with severely
impaired hepatic function. Dosage reduction may be indicated. But
dosage  adjustment  is  unnecessary  in  patients  with  decreased  renal
function.58
DRUG INTERACTIONS
1.  Alcohol  should   be  avoided  because  metronidazole  and
alcohol  together  can  cause  severe  nausea, vomiting,
cramps, flushing  and head ache.
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2.  Disulfiram like reaction may result in confusion and
psychotic reactions.
3.  Cimetidine increases blood levels of metronidazole.
4.  Cholestyramine reduces blood levels of metronidazole by
reducing its absorption.
5.  Metronidazole   should   not   be   combined   with
Amprenavir  for  treating  HIV  because  Amprenavir
contains   propylene    glycol.  Metronidazole   blocks   the
breakdown  of  propylene   glycol  in  the  liver  leading to
accumulation  of  propylene  glycol  in  blood. This would
cause seizures, increased heart rate and kidney failure.
6. Barbiturates cause increased metabolism of  Metronidazole,
thereby the concentration of  Metronidazole  is  decreased.
INDICATIONS
1.  Bacterial infection:
1 a. Serious   infection  caused  by  susceptible   anaerobic  bacteria
such  as  Bacterioides  fragilis  ,Clostridium,  Fuso  bacterium,
Peptostreptococcus  and  peptococcus  species.
1 b. Mixed aerobic and anaerobic infections
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2. Antibiotic  induced  diarrhoea  and  colitis including  pseudo
membranous  colitis  caused  by  Clostridium  difficele.
3. In  multi drug  regimens  for  the  treatment  of  Helicobacter
pylori  associated  peptic  ulcer  disease.
4.  Bacterial  vaginosis –In  1995  Canadian  STD  guidelines
recommended   metronidazole   for   the   treatment   of   this
condition.
5. Periodontal  diseases  like  acute  necrotizing  ulcerative
gingivitis    caused   by   spirochetes  ,Fusobacteria   and
bacterioides  species.
6. Protozoal  diseases  like  Trichomoniasis  in   men  and  women,
hepatic  and  intestinal  amoebiasis,Giardiasis
7. Acne  rosacea
CONTRA INDICATIONS
o  Hyper sensitivity to metronidazole
o  Patients with active neurological disorders or history of blood
dyscrasias
o  First  trimester  of  pregnancy.In  addition , it  is  advisable   that
administration   be   avoided   during   the   second   and   third
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trimester.  Its   use   requires   that   the   potential   benefits   be
weighed  against  the  possible  risks.
o  Lactation-unnecessary exposure to metronidazole should be
avoided. If  a  nursing  mother  is  treated  with  metronidazole
the  breast   milk  should  be  expressed  and  discarded  during
treatment. Breast feeding can be resumed 24-48 hours after
treatment.
ADVERSE EFFECTS
CVS:  Palpitations and chest pain
CNS: Peripheral neuropathy, Seizures, transient   ataxia,
dizziness, drowsiness, confusion, insomnia, headache, incoordination,
ataxia and encephalopathy.
DERMATOLOGICAL:  Urticaria, flushing, rash, pruritus, furry
tongue, glossitis, stomatitis and acute exacerbation of candidiasis.
Rarely   can  cause   Steven   Johnson   syndrome59  ,toxic   epidermal
necolysis.But  recent  reports suggest  concomitant  administration with
Mebendazole  increases  the  risk  of  SJS and TEN
GIT: Diarrhoea, nausea, vomiting, unpleasant metallic taste,
anorexia, epigastric distress, constipation, dry mouth, glossitis,
stomatitis, and candidiasis.
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GENITO  URINARY: Dysuria,proliferation  of  candida  albicans
in   the   vagina,vaginal  dryness  and  burning .
  Dysuria, cystitis and darkening of urine due to the metabolite of
Metronidazole.
HAEMATOLOGICAL:  Transient eosinophilia or leucopoenia
HYPERSENSITIVITY: Erythematous rash, urticaria, serum
sickness like reaction.
ENDOCRINOLOGICAL:   Gynaecomastia
DOSAGE
Available as injection, oral tablets, vaginal gel, vaginal cream,
vaginal inserts topical cream and topical gel.
Adults :   oral  500 mg  every  8  hours (7.5  mg/kg  every  6-8
hours)  to  a  maximum  of  4 g/24 hours.
IV -500mg  by  IV  infusion  every  8  hours   to  a  maximum  of
4 gm /24 hours. IV infusion at the rate of 5 ml/minute.
Children :  30  mg/kg  /dayIV  in  3  divided  doses  or  15-30
mg/kg/day  orally  in   3-4  divided  doses.
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Bacterial vaginosis:  Adult dose of 500 mg orally twice a day
x7 days    Or
Metronidazole  gel  0.75 % one  applicator  full  intra  vaginally
twice  daily x  5  days
Or
Metronidazole 2 gm orally in a single dose.
Routine treatment of male sexual partners is not necessary.
ORAL PROBIOTICS -CAPSULE LACTOBACILLUS
DEFINITION
Probiotics are a mixture of putatively beneficial lyophilized
bacteria given orally.45
HISTORY
Probiotic means ‘for life’. Metchinkoff  in  20th  century
suggested  the  possibility  of modification  of  gut   flora  by  replacing
the  harmful  microbes  by  useful  microbes.
Henry Jissie isolated Bifidobacterium for managing diarrhoea.
Alfred  Misside  in  1970  isolated  E.coli  strain which  was   followed
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by   isolation   of   Metchinkoffs   bulgarius   bacillus   later   called   as
Lactobacillus  bulgarius.
          In 1985 Lactobacillus acidophilus was isolated. The term
probiotics was introduced in 1983. Later Lactobacillus species.
Lactobacillus rhamnosus and reuteri were found to have
beneficial effects on urogenital tract infections.
LACTOBACILLUS
Lactobacilli are rod shaped gram positive, fermentive,
organotropes.  They   are   usually   straight   although   they   can   form
spiral   or   coccobacillary   forms   under   certain   conditions.  They  are
found in pairs or chains of varying length. They  derive  energy   from
the  conversion  of  glucose  to  lactic  acid   during  fermentation. They
generate ATP by   nonoxidative substrate level phosphorylation.
They  have  a   generation  time  ranging  from  25  minutes  to
several   hundred   minutes.   They   grow   optimally   between   the
temperature  of  30  and  40  degree  celsius.
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MECHANISM OF ACTION
1.  The   lactobacillus  strain, colonises  over  a  sufficient  period  to
confer  health  benefits  to  the  host. Adhesion   and  colonization
of  the  vaginal  epithelium  by  the  lactobacillus  provides46  an
effective  barrier  against  pathogenic  vaginal  organisms.
2. The  dried  lactobacilli  used  in vaginal  suppositories  appear
to  be  capable  of  hydrating  from   the  capsule  and  interferes
with  pathogenic  organisms.
3.  Most  urogenital  micro flora  originate  from  the  gut  and
ascend via  the  rectum.47
4. DNA  extracted  from  probiotic  organism  could  mediate  anti
inflammatory  activity  through  toll  like  receptor  9  signalling
pathway.
5. Modulation  of  immunity  by  production  of  bio surfactants  and
collagen  binding  proteins  that  inhibit  pathogen  adhesion.48,49
6.  L.rhamnosus  and  L.  reuteri   adhere  to  cells  ,  persist  ,multiply
and  prevent  adhesion  of  other  pathogenic  organisms.
7. They  produce  lactic acid, hydrogen  peroxide , reutericin  and
bacterioicin  that  are  antagonistic  to  pathogen  growth.50
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8. They resist vaginal microbicides including spermicides.
9. Competition  for   nutrients  which  are  essential  for  the
survival  of  pathogens.
10.    Stimulate the   secretary   local IgA for combating the infection.
11.  Natural   vaginal  strain  L.jensenii  being  engineered  to   deliver
the  potent  HIV  inhibitor  cyanovirin  is  under  study.
EFFICACY AND SAFETY
Effective  in  bacterial   vaginosis,  prevent   the  development  of
yeast  vaginitis , inhibits the  growth  of  Candidia  albicans.
COMPOSITION
Each capsule contains
        Equal   proportion   of   1   billion   C.F.U   of   Lactobacillus
rhamnosus  GR-1 and  Lactobacillus  reuteri  RC - 1450,51
      The   unique   capsule   technology   protects   the   strains   in   the
canister   against   gastric   acid   by   using   a   spherical   polysaccharide
matrix. The matrix releases the live protective bacteria in the small
intestine. In  Indian  women   Lactobacillus  rhamnosus  GR-1  and
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Lactobacillus   reuteri    RC-  14   are   the   more   common    strain.   L.
rhamnosus  are  particularly  effective  in  inhibiting  growth , adhesion
and  biofilm  formation  against  gram  negative  pathogens  and
Candida  albicans.
While    L.reuteri   RC-14   is   effective   against   Gram   positive
pathogens  such  as  Staphylococci, enterococci   and   Streptococci.
A  combination  of  such  type  of  lactobacilli  can  be  more  useful   as
a  probiotic.  So we had taken these strains in our study.
INDICATION
1. Bacterial vaginosis, Yeast vaginitis, urinary tract infection and its
recurrence.
2. Bacterial  vaginosis  leading  to  urethritis, cystitis, urethral
syndrome,post  catheterization  syndrome.52
3. Bacterial   vaginosis   increasing   the   risk   of   PID  ,
cervicitis,endometritis,pre mature  rupture  of  membrane, abortion
and  preterm labour.
4.  Treatment  of  Bacterial  vaginosis  prior  to  in  vitro  fertilization
procedures.
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DOSAGE AND DURATION
1 Capsule  bid  for  the  first  30  days  followed  by
1 Capsule o.d for the next 30 days.
         Preferably  to  be   taken  along  with  meals   with  a   glass  of
water.
         The total duration of therapy is 60   days.
ADVERSE EFFECTS
       Rare cases of lactobacillemia have been reported in severely
immunosuppressed  individuals.  On  the   other  hand  ,  in  HIV  affected
persons  reduce  shedding  of  the  virus.
       In cardiac valve replaced patients, can produce valve sepsis.
Some cases of liver abscess have been reported.
STORAGE
Capsules  are  to  be  stored   in  a  cool , dry place  and  to  be
Protected  from  light  and  heat.
The lid to be replaced immediately after taking the capsule.
PRESENTATION
Canister containing 10 capsules and 30 capsules.
Aim and
Objectives
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AIM  & OBJECTIVES
     1.  To   analyse   the   epidemiological   pattern   of   the  disease
among  the  study  population.
      2. To compare the efficacy of metronidazole and lactobacillus in
the management of bacterial vaginosis.
      3. To evaluate safety, adverse effects, compliance of
metronidazole and lactobacillus.
4. To monitor the recurrence of Bacterial vaginosis following
each therapeutic modality.
Materials and
Methods
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MATERIALS AND METHODS
TRIAL DESIGN
Prospective, open labelled, comparative clinical trial with the
approval of ethical committee.
STUDY POPULATION
Hundred patients with bacterial vaginosis   diagnosed on clinical
grounds, Amsel’s criteria, Nugent’s scoring system, attending the
female STD out patient clinic of Institute of Venereology, Chennai for 2
years from 21.8.2008 to 20.8.2010.
INCLUSION CRITERIA
1.   Patients aged above 18 years.
2.  Those who fulfilled Amsels and Nugent’s criteria for
bacterial vaginosis.
3. Those  who  were  willing  to  come  for  the  follow  up.
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EXCLUSION CRITERIA
1.  Patients aged less than 18 years
2.  Pregnant individuals
3.  Lactating mothers
4.  Treatment with  any  antibiotics  6  weeks  prior  to  study
period.
5.  Patients with other causes of vaginal discharge
METRONIDAZOLE GROUP
1.  Known hypersensitivity to metronidazole.
2. Underlying neurological disorder
3. Alcohol   consumption
LACTOBACILLUS   GROUP
1. History of any drug hypersensitivity
2. Cardiac valve replacement surgery
3. On immunosuppressive drugs
4. Severe immunosuppression
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WITH DRAWALS AND DROPOUTS
          Subjects were informed that they were free to dropout from the
study at any time, without stating any reason and records were
maintained.
TREATMENT PROTOCOL AND METHODOLOGY
Hundred patients were randomly allotted to the two groups(50
each) to receive either tablet metronidazole 400 mg bd for 7 days orally
or capsule Lactobacillus 1 bd for one month followed by 1 od for the
next month orally.
The   study   was   approved    by   the   Institutional   Ethical
Committee, Government   General  Hospital  &  Madras  Medical
College,  Chennai  .  All  patients  signed  a  written    informed  consent
document.
EVALUATION AT THE FIRST VISIT
During the screening period all the patients were evaluated as
Follows:
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History
General examination
Systemic examination
Genital examination, Sniff / whiff test, vaginal pH
          Saline mount, KOH examination,
          Gram staining of vaginal smear.
          Gram staining of endocervical smear
Endocervical   swab for gonococci culture
          Urine examination for albumin, sugar, cast
          VDRL, VCTC tests
MONITORING AT FOLLOW UP VISITS:
The patients were followed up at one week, one month, and 2
months 6 months after starting treatment.
At each visit vaginal pH, Sniff test, Whiff test, saline mount, KoH
test and gram staining were repeated.
          USG   was   done   at   the   end   of   2   months   of   initiation   of
treatment.
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PROCEDURES
COLLECTION OF SPECIMEN
The patient was asked to lie in the lithotomy position. Cusco’s
self   retaining speculum was placed in position. Vaginal  smear  was
collected   from  the   lateral   or   posterior   fornix   of   vagina   with   a
sterile  cotton  swab. An endocervical swab was taken by inserting the
swab 1-2 cm in to the endocervical canal and by rotating the swab for
10-20 seconds. It was subjected to Gram stain and culture for
Gonococci.
TESTS OF SPECIMEN
1.  Vaginal pH test:
The  vaginal   swabs  were  touched  on  the pH  paper  reading
ranging  from  3.5  to  6 .0. Otherwise, the  pH  paper  was  touched  to
the   tip   of   the   vaginal   speculum    after   removing   it    from   the
vagina   or  pH  paper  directly  touched  to  the  wall  of  the  vagina.
The pH paper was not   allowed to contact with cervical secretion.
CUSCO’S BIVALVED,SELF RETAINING SPECULUM
EXAMINATION
CAPSULE LACTOBACILLUS
pH PAPER TEST
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READING
Normal adult vagina has an acid pH of 1- 4.5. In bacterial
vaginosis the pH   is   raised above 4.5
Presence   of   menstrual   blood,  cervical   mucus,  semen   and
Trichomonas  vaginalis  infection  may  also  rise  the  vaginal  pH.
2.  AMINE TEST
A  drop  of   vaginal   fluid   was  put   on  a   clean  microscopic
slide.
To   this  one drop of  10 % KOH solution was added.  The  slide
was   brought   close   to   the   nose   to    smell   the   amine   odor.  An
intense, putrid fishy odor denoted a positive reaction.
3.  MICROSCOPY
Wet mount test:
           A  drop  of  normal  saline  was  put  over  a  clean , grease  free
microscopic  slide. To  this  a  drop  of  vaginal  fluid  was  added  and
mixed  well.  A   cover slip  was  put   over  the  mixture ,so that  there
was   a  uniform   spread   without   air   bubble.  The  slide  was  observed
under 40 x magnification of the objective.
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READING
            Presence of clue cells suggested the diagnosis. ( A  clue  cell  is
a  squamous   epithelial  cell  with  many coccobacillary  organisms
attached  to  its  surface  giving  it  a  granular  surface. The cells  do  not
have  a  well  defined  edge  because  of  the  presence of  bacteria  and
disintegration  of  the  cell ).
Gram staining of the smear:
A   vaginal smear was   prepared on clean, grease free
microscopic slide by rolling the swab on the slide.
The smear was air dried and heat fixed. Crystal violet solution
was  poured  over  the  slide  and  left  for  one  minute  and  washed
with  distilled water.
Gram’s iodine solution was added on the slide and kept for one
minute and washed again with water.
The slide was held between the thumb and forefinger and  flooded
with  a  few  drops  of  the  acetone  - alcohol  decolourizer  until  the
violet colour washed off.
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The slide was washed with running water.  Carbol fuschin
solution  was  poured  over  the  slide  and   allowed  to  act  for  one
minute.
The  slide  was  washed  with  water  and  blotted  by  drying  in
between two blotting papers.
A   drop   of   liquid   paraffin   was   put   over   the   slide   and
observed  under oil immersion.
Reading:
Gardnerella vaginalis -Gram variable to Gram negative rods small
(1.5-2.5 micron x 0.5 micron) shows variation in shape.
Mobiluncus species   - Slender (0.3- 0.4 micron), slightly  curved
rods, either  singly  or  in  pairs  with  the  appearance  of  gull  wings.
M.curtisii is Gram intermediate
M.mulieris is Gram negative
Lactobacillus   -    Seen normally in vaginal secretion as Gram
positive rods. These were markedly reduced in BV.
Clue cells   - epithelial cells coated with bacteria.
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Grams staining reagents
 Solution A :    Crystal violet powder    2 gram
Ethyl alcohol                   20 ml
Solution B               :    Ammonium oxalate       0. 8 gram
Distilled   water                100 ml
Mix solutions A and B and filter.
2.   Grams   Iodine
 Potassium   iodide      2 grams
 Iodine crystals                1 gram
Add 100 ml distilled water
    3.  Decolourizer
Acetone                            50 ml
95 % Ethyl alcohol           50 ml
      4. Counter stain
 Stocking solution Safari or Carol fustian 2.5 gram
                                          95% Ethyl alcohol 100 ml
            Working   solution - Stock solution 10 ml
                                                Distilled water 100 ml
CLUE CELLS IN SALINE MOUNT
CLUE CELL IN GRAM’S STAIN
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GRAM POSITIVE COCCOBACILLI IN GRAM’S STAIN
MOBILUNCUS IN GRAM’S STAIN
LACTOBACILLUS IN GRAM’S STAIN
GARDNERELLA  VAGINALIS IN GRAM’S STAIN
Observation
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OBSERVATION
DEMOGRAPHIC CHARACTERS
Group 1 Group2 p  value
Age 32.3_+ 8.9 31.4_+ 8 0.25
Duration 2(0.06-120) 2(0.3- 120) 0.22
PVD 21 17 0.57
Obstetric history 43 42 0.25
Partner  assessment 11 11 0.78
Menstrual history 42 44 0.59
In this trial the   mean age of patients was 32.4- + 8.4 years with
the P=0.25 in the matched groups. The highest age was 51 years and the
lowest   age   was 20 years.
         There was no significant difference in the mean age between group
1 and group 2 (P=0.25).
DURATION OF SYMPTOMS
There was no significant difference in the median duration
between group 1 and group 2 (p=0.22).
The     average  period  of    duration  of  the  disease    was  about  2
months which was   comparable in between   the   two   groups.
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MENSTRUAL   HISTORY
Menstrual period was regular in 86 individuals out  of  100
patients  ,  irregular   menstrual   cycle   observed   in   10   out   of  100
patients and 4 patients attained menopause.
The proportions of   menstrual history were comparable in   both
the groups. (P value = 0.59).
COMPLAINTS
COMPLAINT GROUP  1 GROUP   2
GENITAL  DISCHARGE 34 33
GENITAL  ITCHING 4 6 P=0.77 (N.S )
GENITAL  MAL ODOR 5 2
  *Chi-square test was used to calculate the P-Value
INFERENCE
? There was no significant difference in the distribution of
complaints between group 1 and group 2 (P=0.77). Out of 100
individuals,    67    patients  came    with  genital  discharge,  10
Individuals with genital itching & 7 individuals with   both
genital odors while 16 were asymptomatic.
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MARITAL   HISTORY
Group 1 Group 2
Marital history N0 (%) N0 (%) P-value
*
Married 46 (92.0) 46 (92.0)
Unmarried 4 (8.0) 4 (8.0) 1.00 (N.S.)
*Fishers Exact Test (2-tailed) was used to calculate the P-Value
Out of 100 patients 92 were married, the remaining 8 of   them
were unmarried. P value was not significant in between the two trial
groups. (P=1.00).
Among  the   married   individuals   57   got   married   before   the
age   of   20  yrs,  26   in  between   21-  25   years   of   age   and   9   got
married  above  the  age  of  25 years.
INFERENCE
? There was no significant difference in the distribution of marital
status in between group 1 and group 2 (P=1.00).
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OBSTETRIC HISTORY
Out  of  the  100  patients  8  patients  were  unmarried, of this  6
individuals denied history of having sex. The rest 2 patients had no
issues.
Among the remaining 92 married patients H/ O normal  delivery
was noted among 58 patients, LSCS among 12 patients, abortion  in  3
patients,  normal   delivery  +  LSCS   in   1  patient,  normal  delivery  +
abortion in 11 patients while nullipara  were  about 7 in number.
In  the  study  population  15  had  no  children ( including
unmarried ) , 21  had  only  one  pregnancy , 34  had  2  pregnancies , 22
had  3  pregnancies  and  8  had > 3  Pregnancies.
          There was no significant difference in the distribution of obstetric
history between Group 1 and Group 2 (P=0.25).
FAMILY PLANNING
On analysing the family planning methods   permanent
sterilization   was   done   in   61  patients  ,  condoms  were   used   by   2
patient’s   partners,  IUCD   was   used   in   18   individuals   while   no
method was adopted by 19  individuals
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? There was a significant difference in the distribution of FP
between group 1 and group 2 (P=0.01).
NUMBER OF SEXUAL PARTNERS
Group 1 Group 2
No. of partners N0 (%) N0 (%) P-value
*
Mono 36 (72.0) 41 (82.0)
Multiple 10 (20.0) 7 (14.0)
Nil 4 (8.0) 2 (4.0)
0.47 (N.S.)
*Chi-square test was used to calculate the P-Value
The number of sexual partners were calculated and analyzed.
Those   who   had   mono   partner     were   77,  multiple   sex   partners
observed in  17  patients , while  6 patients denied  having  sexual
contact.
The  proportion  of   number  of   partners  were  comparable  in
between  the  two  groups.( P = 0.47)
PARTNER ASSESSMENT
  On analyzing the sex partners of   the affected individuals, non
specific urethritis was noted in 10 patient’s partners, balanitis among 6
CONTRACEPTIVES &  ASSOCIATION OF
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partners while no complaints among partners. 2 patient’s partner had
genital  wart,  3  of  the  partners  were  PLHA,  1  positive  for  TPHA?    6
patients   had no sexual partners. 30 partners did not come for
evaluation.
? There was no significant difference in the distribution of partner
assessment in between group 1 and group 2 (P=0.78).
CLINICAL FEATURES
Group  1 Group  2 P  value
Vaginal  discharge 28  +  20 25  + 17 0.23
Saline mount 48 44 0.13
KOH  mount 42 38 0.45
Vaginal pH 50 55 0.28
Cervix- Normal 36 35 0.36
VAGINAL DISCHARGE:
       Vaginal discharge was profuse among 53 patients, moderate in 37
patients. P= 0.23 in    between the two groups (in significant).  90 % of
the   study  population  showed   vaginal  discharge, while  84 %  came
with   the   complaint   of   vaginal  discharge.  16  %    were  unaware  or
asymptomatic about   the vaginal discharge.
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There was no significant difference in the distribution of vaginal
discharge in between group 1 and group 2 (p=0.23).
SALINE MOUNT FOR   CLUE CELLS
Saline  mount  showed  clue  cells  among  90  patients, clue cells
and  pus  cells   seen  in  2  patients,  clue  cells   absent   in 8 patients.
(p  =  0.13  in  significant)  Clue  cells  were  positive  in  92  % of  the  study
population
There was no significant difference in the distribution of saline
mount between group 1 and group 2 (P=0.13).
KOH  EXAMINATION
80 Patients showed positive whiff test and 20 patients were
negative for whiff test. Both the group were comparable based on
amine test.
VAGINAL pH
Vaginal pH was < 5 in 11 patients, 5- 5.5 in 72 patients and > 5.5
in 17 patients. (P = 0.08).
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There was no significant difference in the distribution of vaginal
pH   between group 1 and group 2 (P=0.08).
CERVIX
There was no significant difference in the distribution of cervical
status between group 1 and group 2 (P=0.36).
ENDOCERVICAL   SMEAR
All the study patients were negative for Gonococci in Gram
staining and culture.
URINE EXAMINATION
Urine samples were examined for sugar, albumin, pus cells and
cast. 1 patient in metronidazole group & 5 patients  in  the  lactobacillus.
Group showed positivity for urine sugar. Of them 4 patients were
known  diabetic  and  2  were  newly  diagnosed.  They  were  sent  to  the
diabetology op.
VDRL & TPHA
2 patients   in the lactobacillus group were reactive to VDRL in
1: 1 & 1: 2 dilutions respectively. But the TPHA reading was negative
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VCTC
In   both   groups   2   patients   were   found   newly   positive   for
HIV  and were  sent  for  CD 4   count  were  > 500  cells / ml   and
they  were  under  regular  observation  in  ART  centre  after  the  study
period.  2 patients were  already  positive  for  HIV  and  were  on  ART
before  the  study  period  itself.
ULTRA SONO GRAM
Ultra sonogram was done at the   end of 2 months. 41 patients in
the  lactobacillus  group  and  44  patients  in  the  metronidazole  group
showed   no   abnormality  in  USG.  While   8   patients   in   the
lactobacillus  group  and  1  patient in metronidazole group showed fatty
changes   in the liver. As we  did  not  take  initial  USG  we  were  not
able   to   correlate   this   finding   with   treatment  outcome.  4  patients
showed other abnormality like fibroid uterus, endometrial hyperplasia.
There was a significant difference in the distribution of USG
between group 1 and group 2 (P=0.01).
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AMSELS  CRITERIA BETWEEN TWO STUDY GROUPS AT
DIFFERENT TIME POINTS
           Patients were assessed based on the following response grading
in their follow up visits.
Amsels   criteria
1 & 2    -    Good response
3- 5     -     No response
AMSEL’S CRITERIA
1    Week
          In metronidazole group good response was   noted   in   46
patients (92%). In lactobacillus group   45 patients (90 %) showed good
response.
1   month
  48 patients in metronidazole group (100 %) and 50 in lactobacilli
(100%) group showed good   response. 2 patients in metronidazole
group were   lost from follow up.
2  month
43 patients (97.7%) showed good response in metronidazole
group,  while  all the  50  patients (100% )  in  the  lactobacilli  group
showed   good   response.  Recurrence   seen   in   1   patient   in
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metronidazole  group  and  6  patients  lost from follow up in
metronidazole group.
6 months
              32 patients (76.2%) in metronidazole group, 47 patients (94%)
in lactobacillus   group showed good response. Recurrence seen in both
groups,  10  (  23.8%  )   in   metronidazole   group   and   3  (6%  )   in
lactobacillus  group. 8 patients lost from follow up in metronidazole
group.
Group 1 Group 2Time point
Amsels
criteria
No (%) No (%) P-value
Good response 0 (0.0) 0 (0.0)Day – 0
No response 50 (100.0) 50 (100.0)
-
Good response 46 (92.0) 45 (90.0)Week – 1
No response 4 (8.0) 5 (10.0)
1.00 (N.S.) #
Good response 48 (100.0) 50 (100.0)Month – 1
No response 0 (0.0) 0 (0.0)
-
Good response 43 (97.7) 50 (100.0)Month – 2
No response 1 (2.3) 0 (0.0)
0.47 (N.S.) #
Good response 32 (76.2) 47 (94.0)Month – 6
No response 10 (23.8) 3 (6.0)
0.01 (Sig.) @
#Fishers Exact Test (2-tailed) was used to calculate the P-Value
@ Chi-square test with Yates’ correction was used to calculate the P-Value
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COMPARISON OF NUGENT’S SCORING BETWEEN TWO
STUDIES GROUPS AT DIFFERENT POINTS OF TIME:
Patients  were  assessed  based  on  the  Nugent’s   scoring system
during  their  follow up  visits  by  the  following  response  grading
          Grade   1 - 0-3 score     as   Good   response
          Grade 2 - 4-6 score as   moderate response
          Grade 3 – 7-10 score as no response to treatment.
Group 1 Group 2Time point Nugent’s scoring
No (%) No (%)
P-value*
Good response 0 (0.0) 0 (0.0)
Moderate response 0 (0.0) 0 (0.0)
Day – 0
No response 50 (100.0) 50 (100.0)
-
Good response 20 (40.0) 28 (56.0)
Moderate response 24 (48.0) 20 (40.0)
Week – 1
No response 6 (12.0) 2 (4.0)
0.16 (N.S.)
Good response 39 (81.3) 42 (84.0)
Moderate response 8 (16.6) 8 (16.0)
Month – 1
No response 1 (2.3) 0 (0.0)
0.56 (N.S.)
Good response 27 (61.4) 49 (98.0)
Moderate response 17 (38.6) 1 (2.0)
Month – 2
No response 0 (0.0) 0 (0.0)
<0.0001
(Sig.) @
Good response 13 (30.9) 39 (78.0)
Moderate response 25 (59.5) 11 (22.0)
Month – 6
No response 4 (9.5) 0 (0.0)
<0.0001
(Sig.)
*Chi-square test was used to calculate the P-Value
@ Chi-square test with Yates’ correction was used to calculate the P-Value
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NUGENT’S SCORING SYSTEM
1  Week:
 In  metronidazole  group, good  response  seen  in  20  patients  (
40% ),   moderate   response  in  24  patients (48%)   and  no  response
to   treatment  in  6  patients (12%).
Under lactobacilli group 28 patients (56%) showed good
response, 20 patients (40%) showed moderate response and no
response to treatment seen in 2 patients (4%).
Two groups were comparable (P = 0.16)
1 month:
In metronidazole group 39 patients (81.3%) showed good, 8
patients(18.4%)  showed  moderate  and 1  patient (2%) did  not
respond  to  treatment. 2  patients  were  lost  from  follow  up.
In the lactobacilli group the response was good in 42
patients(84%)  and moderate response in 8 patients (16%).
          Two groups were comparable (P = 0.56)
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2 months:
27 patients (61.4%) showed good and 17 patients (38.6%)
moderate response to treatment. 6 patients were lost from follow up in
metronidazole group.
In lactobacilli   group 49(98%) showed   good and 1 patient (2%)
showed moderate response to treatment.
Lactobacillus group was better than metronidazole group
(P =<0.0001)
6 months:
Under metronidazole group 13 patients (30.9%) showed good, 25
patients (59.5%) elicited  moderate  and  4  patients (9.5% )  showed  no
response  to treatment. 8  patients  were  lost  from  follow up.
In lactobacillus group 39 (78%) showed good and 11(22%)
showed moderate response to treatment respectively.
Lactobacillus   group showed better therapeutic response in this
period. (P < 0.0001)
AMSEL’S    CRITERIA
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DISCUSSION
DEMOGRAPHIC CHARACTERS
AGE
The mean  age  of    patients  in  the  study  group  was    32.4-+  8.4.
This  correlated  with  the  earlier  reported  finding  that BV was  more
common  in  the  sexually   active, reproductive age group.59
DURATION
The mean duration of symptoms in the study was 2 months. The
longest period   observed was 10 years and the shortest period, 1 week.
This depends upon the individual’s sensory adaptation with the existing
disease.
COMPLAINTS
Genital   discharge   was   given   as   a   chief   complaint   in   67
patients , genital itching was noticed in 10  individuals and genital odour
in 7  patients.
16 patients were asymptomatic.
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MENSTRUAL   HISTORY
Most of them (86 %) had regular menstrual cycles. There were no
menstrual disorders in the   patients.
MARITAL STATUS
In our study 92% were married. In the previous Patiala study done
in 80 randomly selected patients, 37.5% were married. Our study
confirms the alteration of vaginal ecoflora after   commencing sexual
activity.60
This study coincides with the previous South Indian study which
stated  the  high  incidence  of  Bacterial  vaginosis  in  married, sexually
active individuals.61
57  /  100  got  married  before  the  age  of  20  years.  This  study
confirms that younger age at marriage has association with
Bacterial vaginosis which was already quoted by Australian study
and the study by Larrson et al.61
PARTNER TRACING
58 patient’s sexual partners were examined   and investigated. 36
individuals showed   no abnormality. Non specific arthritis was seen
among  10  patients , Balanitis  noted  in  6  partners  , 2  with  genital
wart, 3 PLHA and 1 showed   TPHA positivity.
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We were not able   to trace all the partners of the patients included
in the study group.
PREVIOUS VENEREAL DISEASE
35  patients   had   come   with   recurrent   episodes   of   Bacterial
vaginosis, 2 patients in the Metronidazole group (genital ulcer -1,
Vaginal candidiasis -1) and one patient in the Lactobacillus   group
presented  with  past  history   of  cervicitis.  One  patient  in  the
metronidazole group had a past history of genital herpes and bacterial
vaginosis.
Our  study  consisted  of  (15  +  20)  35  recurrent  cases  and    65
newly detected Bacterial vaginosis patients.
ASSOCIATED OTHER DISORDERS
7 patients in each group had associated systemic disorders. In  the
Metronidazole  group   1 patient had diabetes  mellitus,  2 had systemic
hypertension, 1 had hypo thyroidism, 1 had  rheumatic fever, 1
had  associated  skin  disorder,  1  patient  was  a  PLHA  on
ART -1.
        In  the  Lactobacillus  group  5  patients  had Diabetes  mellitus ,
1 had  Oral  candidiasis, 1  was a PLHA  on  ART.
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          In  each  group  2  patients  found  newly  positive  for  HIV  and
were  referred  to  ART  centre . 2  patients  in  the  Lactobacillus  group
were  reactive  to  VDRL  in  1:1 and  1: 2  dilution  but  none  of  them
showed   TPHA   positivity .
OBSTETRIC HISTORY
This  study  outlines  the   direct  correlation  of  the  number  of
pregnancies   and   the   incidence   of   Bacterial   vaginosis.  Australian
study also correlated the above point.63
The two trial groups had comparable values (P=0.25)
FAMILY PLANNING
Majority had undergone permanent sterilization   process 61/100.
Intra uterine devices were used in 18 patients. Only 2 patients used
barrier methods.
As  barrier  methods  are  cited  to  have  some  protective  effects
against  acquisition  of  Bacterial  vaginosis , this  study  correlated  the
preventive  effect  of  condoms   as  barrier  users   had  less  prevalence
compared  to  other  modes  of  contraception.
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CLINICAL DETERMINANTS
SYMPTOMS
In    the   study   done   by   Mathew   R  et   al   in   pregnant
individuals , those who were  in  the 2nd  trimester  out  of  200, 50  were
asymptomatic.64 Though   it   included   only   pregnant   patients  ,   the
study   showed that  25%  were   asymptomatic.  In  our  study  16% were
asymptomatic.
VAGINAL DISCHARGE
Vaginal  discharge  was  profuse  in  53  patients  and  moderate
among  47  patients. 90 % showed abnormal vaginal discharge.
CERVICAL STATUS
Cervix   was   normal   in   71   patients,  eroded   cervix   noted
among  21  patients  and  nebothian  follicle  in  2  patients. (P = 0.36)
LABORATORY INVESTIGATION
Saline mount:
93 / 100 individual’s vaginal discharge    showed positivity for
clue cells on saline mount.
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Whiff test
     80 % showed positivity for Whiff test.
Vaginal pH
All  of  them  had  alkaline  vaginal  discharge.  Vaginal   pH    was
4.5 – 5  in  11 , 5-5.5  in  72  patients  and  > 5.5  in  17  individuals.
ULTRA SONOGRAM
USG   was   normal  in  85   patients  ,   9   patients   showed   fatty
liver  1  showed  L adnexal  cyst , 2 had  fibroid  uterus , 1  patient  had
adeno cystosis and  endometrial  hyperplasia  ( P =  0. 01 significant)
Out   of   9   individuals   with   fatty   liver,   8   were   in   the
Lactobacillus  group, 1 from the Metronidazole  group. This  association
has  to be looked  for  in  further  studies  with  lactobacillus.
THERAPEUTIC EFFICACY
Therapeutic  efficacy  was  observed  at  the  end  of  1 week, 1
month , 2 months  and  6  months  of  starting  treatment.
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Analysis of treatment response was based on Amsels criteria   and
Nugent’s scoring system.
On  comparing  the  two  groups  based  on  Amsel’s     criteria  at
1  week ,1month  and 2 months  period  both  the  drugs  groups   had
comparable  therapeutic  benefits.  But  after 6  months  the  P  value
was  significant  0.01.Metronidazole  group  showed  good  response in
76.2%  and  lactobacillus   group  showed  good  response   in  94%
          On   comparing   the   two   groups   based   on  Nugent’s   scoring
system   at   1   week   and   1   month   period   both   the   groups   were
comparable.  While  at  2  months  and   6  months  period  lactobacillus
group  was  better  than  metronidazole  group ( P  =  < 0.0001  in  both
time  period ) At  the  end  of  study  period  in  metronidazole  group
30.9  %   showed   good   therapeutic   response   and   59.5  %   showed
moderate  response.
          In lactobacilli group, 78% showed good and 22% showed
moderate response. In  the  metronidazole  group  8  patients  were  lost
from   follow  up.
          The follow up period was very long. The treatment   course also
differed. For  metronidazole  7  days  course while  for  lactobacilli
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group  the  treatment  period was  2 months. The cost was also high for
lactobacilli.
          After  2  months  of  therapy,  USG  showed  fatty  liver  changes
in  8 patients  under  lactobacilli  group  and  1 in  metronidazole  group.
In literature  few  cases  of  liver  abscess  reported  after  lactobacillus
ingestion. Whether  our  finding  of  fatty  changes  in liver  was  due  to
lactobacilli  was questionable. It  would  have  been  a  valid finding  if
USG  was  done  at  the  initial  visit  and  repeated at  follow up  visits.
This is the constraint in our study. But  this  is  to  be  carefully  looked
for  in  further  studies.
        In  the  study  done  by Reid  G et al, oral  lactobacillus for  60 days
was compared  with  placebo. The study showed no adverse effects in
lactobacillus users. Culture  findings  suggested  a  significant  depletion
in   yeast   and   coliforms   at   day  28,  60   and  90   for   lactobacillus
treated group versus controls. Microscopy revealed  restoration  of
normal  lactobacillus  colonized  microflora  in  37%  women   during
lactobacilli   treatment   compared   to   13%   in    the   placebo   group.
(P=0.02)65
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The   Nigerian   study   which   compared   the    efficacy  of   oral
lactobacillus  for  7  days  with 0.75 % metronidazole  gel it  showed  90
%  efficacy in  lactobacillus  group and  55 %  improvement  in
metronidazole   group.  This   report  was   taken   at   the   end   of   1
month.66
In  another  study  by  Kingsley  Anukkam  et al which  included
2  study  groups  both  groups  initially  had a  course of  Metronidazole
for  1  week . After that   group 1 patient were treated with  Probiotics
and Group 2 with a Placebo. 88%  in  the  probiotic group and  40 %  in
the  Placebo  group  were  cured  at  the   end.67
These   studies   like   our   study   showed  the   effectiveness   of
probiotics   in  the  management  of  Bacterial  vaginosis. In  this era  of
emerging  antibiotics  resistance ,chronicity  and  the  recurring  nature
of  BV  they  are  the   definite  doubtless  alternative  to  antibiotics.
SIDE EFFECTS NOTED
In  Metronidazole  group  4  patients  complained  of  nausea  and
5  patients complained  of  metallic  taste.
3   in   the   Lactobacillus   group   and   1   in   the   Metronidazole
group were  treated  for  Candidiasis  in the  follow up  period.
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On   doing   ultra  sonogram   8   patients  (16  %  )  in   the
Lactobacillus  group  and  1 ( 2 % ) in  the  Metronidazole  group  25
showed  fatty  change  in  the  liver. This is to be associated in further
studies.
RECURRENCE
Based on Amsel’s criteria at the end of 1 month both the groups
showed good response in all the patients. But recurrence noted in 1 and
10 patients at 2 months and 6 months period in metronidazole group and
in 3 patients in the lactobacillus group at 6 months period.
Based on Nugent’s scoring system ,in  metronidazole  group  at  2
months   of   completing   treatment   good   and   moderate   response   to
treatment  was   noted  in   61.4%  and  38.6% respectively. But  at  the
end  of  6  months  period   no  response  to  treatment  seen  in  9.5% .
While  lactobacillus  group  showed  nil  recurrence  at  the  end  of  6
months.
Conclusion
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CONCLUSION
1.  Bacterial vaginosis   was seen commonly in the age group of 24 –
40 years.
? Menstrual cycle irregularities had   no association with
prevalence. BV   was  seen  in  both  married  and  unmarried  as
well   as   those   who  never  had  sexual  intercourse.  But  the
incidence in unmarried & those who never had sexual intercourse
is minimal.
? The earlier age at marriage was directly proportionate   to
incidence of BV.
? 77 %, Majority had mono partners, 17 % had multiple sexual
partners and 6% denied   sexual exposure.
? The   mode of delivery had no significant association. Number of
deliveries was directly proportionate to acquisition of BV.
? Moderate to profuse genital    discharge was the commonest
observed finding.
? In saline   mount 90 % showed clue cells positivity. Whiff test
was   positive  in   80%  ,  Vaginal   pH   was    >  5   in   all   the
patients.
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2.   By  Amsel’s  criteria , the  two  groups  were   comparable  in  the
1  week, 1  month, and 2 months period (P = 1, 0.56, 0.47) while at 6
months period  lactobacillus  group  was  better  than  metronidazole
group
By  Nugent’s    criteria,  the  two  groups  were  comparable  in  the
1 week, 1 month period But at 2 months and
6  months period  lactobacillus group showed better therapeutic benefits.
3.  Few tolerable side effects were noticed in the metronidazole
group. Though  both  the  groups  completed  their  treatment  schedule ,
8  patients  lost  during  follow up in the metronidazole group.
4.   Recurrence was noted in both the study groups at the end of 6
months, based on Amsel’s criteria. In metronidazole group 1 and 10
patients showed recurrence at 2 months and 6 months period. In
lactobacillus group 3 patients showed recurrence at the end of 6 months.
           Recurrence was noted   in 4 patients (9.5%)  in the metronidazole
group    at    the    end    of    6    months,  while    no  recurrence  seen  in
lactobacillus users based on Nugent’s scoring system.
Annexure
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Proforma
PROFORMA
COMPARATIVE STUDY IN THE MANAGEMENT OF BACTERIAL
VAGINOSIS LACTOBACILLUS      Vs      METRONIDAZOLE
NAME                  AGE                    OCCUPATION              OP/ IP NO
ADDRESS
COMPLAINTS:
Abnormalgenitaldischarge Burningmicturition
Genital   ulcer  Menstrual  irregularities
Genital   swelling  Inguinal   swelling
Genital itching Others
HISTORY    OF   PRESENTING   ILLNESS
 1. Genital discharge
      Duration Smell  :  Foul   smelling / not so
      Itching: Present / Absent        Associated with menstruation /
Sexual intercourse / Nil
2. H / O  Recent  intake  of  antibiotics  for  long  duration (  More  than  1  month )
3.  Others if any specify
TREATMENT HISTORY:
Underwent any treatment   / Nil
PAST HISTORY:
1.   Any previous episode of genital ulcer / Nil          Whether treated / Not
                                       Genital discharge / Nil           Whether treated / Not
2. H / O    DM / HT / PT / Bronchial   asthma
PERSONAL HISTORY:
            Diet / Alcohol / Smoking
MENSTRUAL    HISTORY:
              Menarche / Menopause                Regular / Irregular        LMP
               Foul   smelling:  Present / Absent
MARITAL HISTORY:
                  MC                                   PMC                            EMC
OBSTETRIC HISTORY:
Gravida Para
IUD /
Abortion
Preterm/
term
B. weight
Post partum
period
FAMILY PLANNING METHOD:
Sterilization                       Temporary Nil
                                              IUD/ OCP / Condom
L/E:
 Inguinal nodes
         just palpable / Enlarged            Discrete / Matted   Tender / Nontender
         Signs of inflammation              Present / Absent
S/ E:    1. External urethral orifice    Congested / Normal
              2. Vagina                               Mass / Ulcer / Growth / scar / Vesicles
                                                            Genital ulcer Single / multiple
Painful/ Painless
              3. Vaginal discharge Scanty / moderate/ profuse
Foul smelling/ Not so
Mucoid / Mucopurulent/ frothy /
thick curdy white/ Homogenous uniformly
adherent
             4. Cervix Healthy / Eroded / IuCD / discharge/ Polyp/
Nebothian follicle / Growth
  EXAMINATION OF ANAL ORIFICE                      ORAL ORIFICE
SKIN / MUCOSA                                                              BONES / JOINTS
   INVESTIGATION
        1. Urine               Albumin                            Hb
                                    Sugar
        2. VDRL                                                       TPHA
3. VCTC
        4. Vaginal discharge
Vaginal  pH Sniff / Whiff Saline  mount 10 % KOH
5.  Smears Taken
Vaginal
Epithelial Clue cell Pus cell Lactobacillus
Cervical Urethral
AMSELS  CRITERIA NUGENTS  SCORING
Vaginal discharge                              (Gardnerella, Mobiluncus, Prevotella / oil field)
2. Vaginal pH                                          1                    2                 3               4
3. Sniff / Whiff                                       < 1              1- 5              6- 30         > 30
4. Clue cells                                             (Lactobacilli / oil field)
5. Lactobacillus                                       > 30            6- 30              1-5           <1
                                                                  BV    = Score    7-10   : Nil BV = Score 0-
TREATMENT   MODALITIES TRIED
1. Tab. Metronidazole 400 mg b.d x 7 days
2.  Cap. Lactobacillus  1 bd  x 1 month,   followed by 1 o d x Next 1 month
FOLLOW UP
                                    1 week           1 month     2 months     6 months
1. Vaginal discharge
 2. Odor
3. Vaginal pH
4. Amine test (Sniff / Whiff)
5. Saline mount
6. Gram stain


Master Chart
No. AG Com Dur PVD O Men Mar NP Con Obs FP VD Cx Sal KOH pH A0D A1w A1m A2m A6m N0d N1w N1m N2m N6m USG
1 36 1 2 1 2 1 1 1 1 1 1 1 1 1 1 5 2 1 1 1 2 3 3 2 2 2 1
2 48 1 6 1 2 3 1 1 3 1 1 1 1 1 1 4.5 2 1 1 1 1 3 2 2 1 1 1
3 51 1 1 1 1 3 1 1 1 4 1 1 4 1 5 2 2 1 1 1 3 2 1 1 1 1
4 23 1 120 1 2 2 1 1 1 1 1 1 1 1 4.5 2 1 1 1 1 3 1 1 1 1 1
5 27 1 0.3 3 2 1 1 1 1 1 1 1 1 2 5 2 1 1 3 2 1 1
6 20 0.3 1 2 1 1 1 1 1 2 1 1 1 1 4.5 2 1 1 1 1 3 2 1 1 2 1
7 22 1 2 3 2 1 1 1 3 4 1 1 1 1 5 2 1 1 1 1 3 2 1 1 2 1
8 35 3 0.3 3 2 2 1 2 1 1 4 1 1 1 1 4.5 2 1 1 1 1 3 1 1 2 2 1
9 26 120 2 2 1 1 1 3 1 4 1 1 1 1 5.5 2 1 1 1 1 3 1 1 1 1 2
10 45 0.1 3 2 1 1 1 1 1 1 1 1 1 1 6 2 1 1 1 1 3 3 3 2 3 2
11 46 2 24 3 2 1 1 1 1 1 1 2 1 1 5.5 2 2 1 1 1 3 3 2 2 2 1
12 41 2 1 1 2 1 1 1 1 1 2 1 1 1 4.5 2 1 1 1 1 3 2 1 1 1 1
13 33 1 1 3 2 1 1 1 4 1 3 1 1 1 2 5.5 2 1 1 2 2 3 1 1 2 2 1
14 21 1 6 3 2 1 1 1 1 6 4 1 1 1 2 5.5 2 1 1 1 2 3 2 1 2 2 2
15 21 1 0.3 3 2 1 2 3 6 2 1 1 6 2 1 1 1 1 3 2 1 1 1 1
16 33 1 0.3 3 2 1 1 2 1 1 1 1 2 1 1 4.5 2 1 1 1 1 3 1 1 2 2 1
17 35 0.3 3 2 1 1 2 2 1 4 1 1 1 1 6 2 1 1 1 2 3 1 1 1 1 1
18 29 1 0.5 3 2 1 1 2 1 2 1 1 1 1 2 5 2 1 3 1 1 1
19 27 1 2 3 2 1 1 1 3 1 1 1 1 1 1 5 2 1 1 1 1 3 1 1 1 1 1
20 36 2 0.1 3 2 1 1 1 1 1 1 2 1 1 2 5 2 1 1 1 2 3 1 1 2 3 1
21 22 1 0.3 3 2 1 1 1 6 4 1 1 4 1 6 2 1 1 1 1 3 1 1 2 2 1
22 43 2 48 1 2 1 1 1 1 1 4 1 1 1 1 5 2 1 1 1 2 3 2 1 2 2 1
23 21 1 0.6 3 2 1 1 1 4 1 4 2 1 1 2 6 2 1 1 1 1 3 1 1 1 1 3
24 26 2 2 1 2 1 1 1 1 3 4 2 1 1 1 5.5 2 1 1 1 1 3 3 1 1 2 1
25 43 1 1 3 2 2 1 1 1 1 2 2 1 1 5 2 1 1 1 2 3 1 1 1 2 1
26 26 1 1 3 2 1 1 1 1 1 4 2 1 1 1 4.5 2 1 1 1 1 3 2 2 2 2 1
27 27 1 2 3 2 1 1 2 1 1 2 2 1 1 6 2 1 1 1 2 3 2 1 1 2 1
28 35 1 2 3 2 1 2 3 6 2 1 1 4 2 2 1 1 1 3 2 1 1 2 1
29 45 1 1 1 1 1 1 1 6 4 1 1 1 1 5 2 1 1 3 1 1 1
30 32 1 3 3 2 1 1 2 2 1 1 1 1 1 5.5 2 2 1 1 1 3 3 2 1 1 1
31 35 1 2 3 1 2 1 1 4 1 1 1 1 1 1 5 2 1 1 1 1 3 2 1 1 1 1
32 45 3 2 3 1 1 1 1 2 3 1 1 1 1 5 2 1 1 1 1 3 1 1 1 1 1
33 27 2 3 3 2 1 1 1 1 2 3 1 1 1 1 5 2 1 1 1 2 3 2 1 1 2 1
34 30 1 3 2 1 1 1 2 5 1 1 2 1 1 6 2 1 3 1 1
35 51 1 1 2 3 1 2 3 1 1 2 1 1 1 5 2 1 1 1 1 3 1 1 1 2 1
36 38 1 6 1 2 1 1 2 1 1 1 1 1 1 1 6 2 1 1 1 2 3 2 2 2 2 1
37 47 1 0.3 1 2 1 1 1 1 3 1 1 1 1 5 2 1 1 1 1 3 2 1 1 2 1
38 26 1 36 1 1 1 1 1 5 4 2 2 1 1 5 2 1 1 1 1 3 2 1 1 2 1
39 32 6 1 2 1 1 1 2 5 1 2 1 1 1 6 2 1 1 1 2 3 2 1 2 2 1
40 45 1 2 1 2 2 1 2 1 1 1 2 1 1 1 5 2 1 1 1 1 3 1 1 2 2 1
41 36 1 66 1.2 2 1 1 1 5 1 2 2 1 1 5 2 1 1 1 2 3 2 1 2 2 1
42 30 60 3 2 1 1 1 2 1 2 1 1 1 6 2 1 1 3 1 1 3
43 37 3 7 3 2 1 1 1 5 1 2 2 1 1 5 2 1 1 1 1 3 1 1 1 1 1
44 41 1 1 1 1 1 1 1 2 4 1 2 1 1 1 5.5 2 1 1 1 1 3 2 1 1 1 1
45 23 1 24 3 1 1 2 3 2 1 1 5 2 1 1 1 1 3 1 1 1 1 1
46 30 1 3 3 2 1 1 1 1 2 3 2 1 1 1 6.5 2 1 1 1 1 3 2 2 2 3 1
47 27 1 1 3 2 1 1 1 1 1 2 2 1 1 5.5 2 1 1 1 1 3 3 2 1 2 1
48 20 1 2 1 2 1 1 2 5 3 1 2 1 1 5.5 2 1 1 3 2 1 2
49 40 1 1 1 2 1 1 1 1 2 4 1 1 2 2 5.5 2 1 1 1 1 3 2 1 1 3 1
50 32 1 2 1 2 1 2 3 1 2 2 5 2 1 1 1 1 3 2 2 2 2 1
GROUP - 1 METRONIDAZOLE
No. AG Com Dur PVD O Men Mar NP Con Obs FP VD Cx Sal KOH pH A0D A1w A1m A2m A6m N0d N1w N1m N2m N6m USG
1 30 1 12 3 2 1 1 1 1 1 2 2 1 1 .5.5 2 1 1 1 1 3 2 1 1 1 1
2 26 1 1 2 1 1 1 1 1 1 2 2 1 1 5 2 1 1 1 1 3 1 1 1 1 1
3 38 1 2 3 2 1 1 1 1 1 4 2 1 2 2 4.5 2 1 1 1 1 3 1 1 1 2 2
4 23 2 1 1 2 1 1 1 1 1 2 1 2 2 5 2 1 1 1 1 3 1 1 1 1 1
5 34 1 24 3 1 2 1 1 1 1 1 1 2 2 5 2 1 1 1 1 3 3 2 1 1 3
6 25 1 1 3 2 1 1 1 2 1 1 1 1 2 2 5.5 2 1 1 1 1 3 1 1 1 2 2
7 35 1 3 2 1 1 1 1 2 1 1 1 5.5 2 1 1 1 1 3 1 1 1 1 1
8 44 2 5 3 2 1 1 2 1 1 1 1 1 1 5 2 1 1 1 1 3 1 1 1 1 2
9 29 1 0.3 3 2 1 1 1 5 2 1 3 2 2 5 2 1 1 1 2 3 1 1 1 2 1
10 27 1 2 3 2 1 1 1 4 1 3 1 1 1 1 5.5 2 1 1 1 1 3 1 1 1 1 1
11 35 1 1 3 2 1 1 1 1 1 1 3 2 2 5.5 2 1 1 1 1 3 1 1 1 1 3
12 34 3 24 3 1 2 1 1 1 1 1 1 1 1 1 5 2 2 1 1 1 3 2 1 1 1 3
13 13 2 3 1 2 1 1 1 2 1 3 2 1 1 1 4 2 2 1 1 1 3 2 1 1 1 1
14 54 1 0.5 3 2 3 1 1 1 5 2 1 1 1 5 2 1 1 1 1 3 2 2 1 2 1
15 30 1 4 3 2 1 1 1 2 1 1 1 6 2 1 1 1 1 3 1 1 1 1 1
16 30 1 1 1 2 1 1 1 1 1 1 2 2 1 1 4.5 2 1 1 1 1 3 1 1 1 1 1
17 38 1 2 3 2 1 1 1 1 1 2 2 1 2 5 2 1 1 1 1 3 2 1 1 2 1
18 33 3 1 3 2 1 1 1 1 1 1 1 1 1 5.5 2 1 1 1 1 3 1 1 1 2 1
19 35 1 3 2 2 1 1 1 1 2 1 1 1 5 2 1 1 1 1 3 1 1 1 1 3
20 30 1 120 3 2 1 1 1 2 1 3 2 2 1 2 5 2 1 1 1 1 3 1 1 1 1 1
21 29 3 2 3 2 1 1 1 1 3 2 1 1 2 6 2 1 1 1 2 3 2 1 1 2 1
22 36 1 7 1 2 1 1 1 1 1 1 2 1 1 1 5.5 2 1 1 1 1 3 2 2 1 1 1
23 34 1 96 2 2 1 1 1 3 1 1 1 1 1 1 6 2 1 1 1 1 3 1 1 1 1 1
24 40 2 1 1 1 1 2 1 1 2 1 1 5 2 2 1 1 1 3 2 1 1 1 3
25 27 1 1 3 2 1 1 1 1 1 1 1 1 1 1 5.5 2 1 1 1 2 3 2 2 1 2 1
26 23 1 0.5 3 2 1 1 1 4 1 3 1 1 1 1 5 2 1 1 1 1 3 1 1 1 2 3
27 30 0.3 3 1 1 1 1 1 3 1 1 1 1 5.5 2 1 1 1 1 3 1 1 1 1 1
28 27 1 1 3 2 1 1 2 1 1 1 1 1 1 1 5.5 2 1 1 1 1 3 1 1 1 1 1
29 37 1 5 3 2 1 2 3 1 1 1 5 2 1 1 1 1 3 2 1 1 1 1
30 40 1 4 3 1 1 1 1 1 1 1 1 1 6 2 2 1 1 1 3 2 1 1 1 3
31 30 1 2 3 1 1 1 1 4 1 1 1 1 1 1 5 2 1 1 1 1 3 1 1 1 2 1
32 28 1 4 3 2 1 1 1 1 2 1 1 2 1 1 5.5 2 1 1 1 1 3 3 2 1 1 3
33 43 1 12 3 2 1 1 1 2 1 1 1 2 1 1 5 2 1 1 1 1 3 2 1 1 1 1
34 38 1 1.5 3 2 2 1 1 1 1 1 1 1 1 1 5.5 2 1 1 1 1 3 1 1 1 1 1
35 37 1 3 3 2 1 1 1 5 2 1 1 2 5.5 2 1 1 1 1 3 1 1 1 1 3
36 21 1 1.5 1 2 2 2 1 3 2 1 1 1 5 2 1 1 1 1 3 1 1 1 1 1
37 27 1 48 1 2 1 1 1 2 2 1 2 2 1 2 5 2 1 1 1 1 3 1 1 1 1 3
38 22 1 24 1 2 1 1 2 1 5 3 2 1 1 1 5.5 2 1 1 1 1 3 1 1 1 1 3
39 23 1 2 1 2 1 1 1 1 1 1 1 1 1 5 2 1 1 1 1 3 1 1 1 1 1
40 26 1 24 3 2 1 1 1 1 2 1 1 1 5 2 1 1 1 1 3 1 1 1 1 1
41 45 1 3 3 1 1 1 2 2 1 1 1 1 1 5 2 1 1 1 1 3 2 1 1 1 1
42 40 0.3 3 2 1 1 1 2 1 1 2 2 1 1 5 2 1 1 1 1 3 2 1 1 1 3
43 45 3 5 1 2 1 1 1 1 1 2 2 1 2 5 2 1 1 1 1 3 1 1 1 1 1
44 20 1 2 1 2 1 1 2 3 2 1 1 1 6 2 1 1 1 1 3 2 1 1 1 1
45 25 1 1 3 2 1 1 1 1 1 3 1 1 1 1 5.5 2 1 1 1 1 3 2 1 1 1 1
46 29 6 1 2 1 1 1 1 2 1 2 1 1 1 6 2 1 1 1 1 3 1 1 1 1 1
47 36 1 3 3 2 1 1 2 5 1 2 1 1 1 5.5 2 1 1 1 1 3 2 1 1 1 2
48 20 1 2 1 2 1 1 1 1 3 2 1 1 1 5 2 1 1 1 1 3 2 2 2 2 2
49 19 3 3 2 1 2 3 2 1 1 5.5 2 1 1 1 1 3 2 2 1 1 1
50 29 1 8 1 2 1 1 2 1 2 1 2 1 1 1 5.5 2 1 1 1 1 3 2 2 1 1 1
GROUP 2 LACTOBACILLUS
KEY TO MASTER CHART
NO -  Serial number
Ag - Age  in years
Com -  Complaint   1- Genital discharge ,2- Itching  ,3- Malodor in genitals
Dur -  Duration  in months
PVD -  Previous veneral disease 1- similar,  2- Other, 3- Nil
O -  Other illness  1- Present , 2- Absent
Men -  Menstrual history   1- Regular, 2- Irregular
Mar -  Marital history  1-  Married , 2- Unmarried
NP -  Number of partner  1- Mono  , 2- Multiple
Con -  Contact tracing   1- Nil , 2- Urethritis, 3 – Balanitis , 4- Others
Obs -  Obstetric history  1- normal delivery, 2- LSCS, 3- Abortion
FP -  Family planning  1-  Sterilization,  2- barrier, 3- IUCD, 4- Nil
VD -  Veneral disease  1- Profuse, 2- Moderate
Cx -  Cervix   1- Normal, 2- Erosion, 3- Other
Sal -  Saline mount  1- Clue cells present, 2- Clue cells absent, 3- Other
KOH - KOH mount   1- Odour present, 2- Odour absent
Ph -  Vaginal pH
USG   -  Ultrasonogram 1- Nil abnormality detected, 2- Fatty change in liver ,
3- Other
A -  Amsel’s criteria 1- <3  No BV, 2- 3 and 4 BV
N –  Nugent’s scoring system  1- Score 0-3, 2- Score 4-6, 3- Score 7-10 0d-
0 Day  1w -1 week  1m – 1 month  2m- 2 months  6m- 6 months
